Kancera applies for new patent

The European Health Data and Evidence Network (EHDEN) and Lundbeck have begun formative stages of neuroscience research with the EHDEN network and potential partners, including other pharma companies. Lundbeck joined the IMI EHDEN Consortium on 1st September 2022 and is now the first partner to join the neuroscience research programme. “This partnership will contribute to the neuroscience ecosystem […]

AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. Lynparza is being jointly developed and commercialised by AstraZeneca and […]

Cyxone, together with its academic partner Medical University of Vienna, has continued to investigate the drug candidate T20K in combination with a kappa opioid receptor agonist. A combination which in pre-clinical experiments demonstrate promising synergistic therapeutic effects and potential disease modifying features in multiple sclerosis. The results build upon previous data which underpin a patent […]

Elicera Therapeutics has presented preclinical proof-of-concept data for its iTANK-platform at the European Society of Gene & Cell Therapy Virtual Congress 2021. Elicera’s technology platform – iTANK (immunoTherapies Activated with NAP for efficient Killing) – has been developed to optimize the effect of CAR T-cell therapies by generating a dual mechanism-of-action. In addition to the […]

AlzeCure Pharma has presented new data showing how substances from the NeuroRestore platform affect relevant signaling pathways in the brain and have effects in various preclinical models that link to depression. “The findings we have seen with our substances indicate that there are also great opportunities for the NeuroRestore platform in other cognitive disorders outside […]

New preclinical data relating to the use of the company’s oncolytic immunotherapy platform for expressing a human IL-2 variant protein has been published in Frontiers in Immunology. The paper was independently authored by researchers at the University of Helsinki and other leading institutions, together with TILT Biotherapeutics. TILT-452 The paper describes a study with TILT-452, […]

Immunicum has announced that the sixth patient has completed the safety period in the ongoing Phase Ib/II ILIAD combination trial with ilixadencel, the company’s cell-based, off-the-shelf immune primer for the treatment of solid tumors. The Dose Escalation Committee (DEC) confirmed there were no dose limiting toxicities, therefore the study can move into the non-staggered inclusion […]